As Pre Implantation Genetic Screening (PGS) becomes now a replacement modality and trend gaining popularity among physicians and patients on claiming its ability to settle on the simplest genetically normal embryo, so it had been logical to review if taking cells from the embryo in its early development will or won't affect its growth as compared to the previous standard technique of ICSI and in comparison to a normally conceived embryos the study also will question if the parameters of the prenatal biochemical standard parameters will have any differences if the embryo is already genetically tested embryo and compare these parameters with non PGS embryos and normally conceived embryos. This study is an ambispective, comparative, cohort, observational, single-center study. The study participants' relevant medical records will be collected and reviewed for the retrospective subjects and after obtaining informed consent for the prospective subjects. The study materials that will be used will include blood tests and ultrasound. The study will involve three study arms
This study is an ambispective, comparative, cohort, observational, single-center study that will be conducted at Wael ElBanna Clinic, a private center that is well equipped for all procedures needed for ICSI and fetal medicine. After obtaining informed consent, the study participants' relevant medical records will be collected and reviewed. Data will be collected from the subjects' medical records. Data will be pooled and presented in aggregate, without identification of individual subjects. The study materials that will be used will include blood tests and ultrasound. The study will involve three study arms: * Arm 1: biopsied ICSI embryos (PGS) * Arm 2: none biopsied ICSI embryos * Arm 3: natural pregnancy embryos
Study Type
OBSERVATIONAL
Enrollment
420
Biopsied ICSI embryos (PGS)
wael Elbanna Clinic
Cairo, Egypt
RECRUITINGFirst primary endpoint
\- Early ultrasound measurements "yolk sac (YS), mean sac diameter (MSD), crown rump length (CRL)", different maternal serum prenatal screening markers for growth and aneuploidy between the three arms\* of the study
Time frame: At pregnancy
Second primary endpoint
\- Second trimetric U/S measurements of fetal growth : U/S measurements of fetal growth using growth curves and measurement of FPI (fetal ponderal index) and fetal weight percentile
Time frame: At 2nd trimester of pregnancy
Third primary endpoint
\- Third-trimester U/S measurements of fetal growth : U/S measurements of fetal growth using growth curves and measurement of FPI (fetal ponderal index) and fetal weight percentile
Time frame: At 3rd trimester of pregnancy
First secondary endpoint
Miscarriage
Time frame: At Labor
Second secondary endpoint
Live-birth weight
Time frame: At Labor
Third secondary endpoint
Preterm labor
Time frame: At Labor
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.